Vimedimex Medi-Pharma JSC (HOSE:VMD)

Vimedimex Medi-Pharma JSC Income Statement

Financials in millions VND. Fiscal year is January - December.

Fiscal Year	FY 2021	FY 2020
Period Ending	Dec 31, 2021	Jan 1, 2021
Revenue	12,318,752	18,142,492
Revenue Growth (YoY)	-32.10%	-
Cost of Revenue	11,250,064	16,638,114
Gross Profit	1,068,687	1,504,378
Selling, General & Admin	915,955	1,317,637
Operating Expenses	915,955	1,317,637
Operating Income	152,733	186,740
Interest Expense	-15,745	-8,065
Interest & Investment Income	5,519	3,411
Currency Exchange Gain (Loss)	-115,776	-140,753
Other Non Operating Income (Expenses)	1,674	8,947
EBT Excluding Unusual Items	28,404	50,280
Gain (Loss) on Sale of Assets	29.09	209.09
Pretax Income	28,433	50,489
Income Tax Expense	9,084	13,140
Earnings From Continuing Operations	19,349	37,350
Minority Interest in Earnings	646.03	-448.46
Net Income	19,995	36,901
Net Income to Common	19,995	36,901
Net Income Growth	-45.81%	-
Shares Outstanding (Basic)	15	15
Shares Outstanding (Diluted)	15	15
Shares Change (YoY)	0.00%	-
EPS (Basic)	1295.00	2390.00
EPS (Diluted)	1295.00	2390.00
EPS Growth	-45.82%	-
Free Cash Flow	-442,484	141,282
Free Cash Flow Per Share	-28657.78	9150.50
Gross Margin	8.67%	8.29%
Operating Margin	1.24%	1.03%
Profit Margin	0.16%	0.20%
Free Cash Flow Margin	-3.59%	0.78%
EBITDA	171,784	204,427
EBITDA Margin	1.39%	1.13%
D&A For EBITDA	19,051	17,686
EBIT	152,733	186,740
EBIT Margin	1.24%	1.03%
Effective Tax Rate	31.95%	26.02%
Revenue as Reported	12,318,752	18,142,492

Source: S&P Global Market Intelligence. Standard template. Financial Sources.